Histidine-rich glycoprotein (HRG) circulates in plasma at a concentration of 2 µM and binds plasminogen, fibrinogen, and thrombospondin.
Introduction
Despite the capacity of the intrinsic pathway to enhance thrombin generation, patients deficient in factor (f.) XII do not bleed. 1 Even patients with f.XI deficiency rarely suffer hemorrhagic complications, except with surgery or major trauma. 2 Because of these observations, it is well accepted that the contact system plays little part in hemostasis and, by extension, it was also thought to be unimportant for thrombosis. However, a number of recent studies challenge this thinking. First, mice with deficiencies of high molecular weight kininogen (HK), bradykinin B2 receptor, f.XII, or f.XI are protected against injury-induced thrombosis and an antibody against f.XI inhibits thrombus formation in a baboon arterio-venous shunt model. [3] [4] [5] [6] [7] These observations raise the possibility that the contact pathway contributes to thrombogenesis. 8 Second, potential physiological activators of f.XII have been identified, which could initiate the contact system at sites of vascular injury. In addition to glycosaminoglycans and collagen, novel activators include polyphosphates and RNA. 9, 10 Polyphosphates, which are released from the dense granules of platelets activated at sites of injury, trigger coagulation in a f.XII-dependent fashion. Likewise, RNA released from the damaged vessel wall also can activate f.XII and RNAase administration to animals attenuates thrombosis at sites of injury; observations that have sparked a renewed interest in the contact pathway. 10 Consequently, it is important to better understand this pathway and how it is regulated.
Histidine-rich glycoprotein (HRG) is an abundant plasma protein whose role is largely unknown. 11 HRG circulates at a concentration of ~2 µM. Its concentration may increase locally because HRG also is found in α granules of platelets where it can be released upon activation.
4 hemostasis as an accessory or adapter protein. 11, 13 In support of this concept, HRG-deficient mice exhibit shortened clotting times. 14 Furthermore, HRG has been shown to inhibit contact activation of plasma in vitro, presumably because the histidine-rich region of HRG binds to negatively charged surfaces and prevents autoactivation of f.XII. 15 Modulation of the contact system may impact thrombosis because studies have linked deficiency of HRG in humans with thrombophilia. 16 The current study was undertaken to more precisely define the role of HRG in the modulation of coagulation.
Methods

Reagents.
Deaminated heparin (MW 6,700), biotinamidohexanoic acid hydrazide (biotin-hydrazide),
Protease Inhibitor Cocktail for His-Tagged Proteins, and silica (0.5 -10 μm particle size) were from Sigma. Dextran sulfate (500 kDa) was from GE Healthcare. Sulfosuccinimidyl HRG was isolated by a modification of a previously published method. 17 Citrated plasma was supplemented with 1 μM Val-Phe-Lys-chloromethyl ketone (EMD Chemicals Inc.), 0.1% Protease Inhibitor Cocktail, and approximately 10,000 kallikrein inhibitory units (KIU) aprotinin
For personal use only. on September 24, 2017 . by guest www.bloodjournal.org From (American Diagnostica, Montreal QC). After centrifugation at 10,000 × g for 30 min at 4°C, any visible lipid layer was removed and solid imidazole was added to 5 mM. Plasma was subjected to chromatography on a 50 ml nickel-NTA agarose column (Qiagen Inc., Mississauga, ON). The column was washed with 5 volumes of 20 mM Tris-HCl, 150 mM NaCl, pH 7.4 (TBS) containing 0.005% Tween 20 (TBS-Tw) and 5 mM imidazole. Successive washes with TBS-Tw contained 5 mM imidazole, 5 mM imidazole plus 10 mM ε -amino caproic acid, 80 mM imidazole, and then 100 mM imidazole. The ε -amino caproic acid was present because plasminogen is a frequent contaminant. 18 Aprotinin was added to the 80 and 100 mM imidazole wash buffers at 10 KIU/ml. HRG was eluted with TBS-Tw containing 250 mM imidazole, pH 7.5. The concentration of HRG was determined by absorbance at 280, using a molecular weight of 67,000 and an extinction coefficient of 0.39 ml/mg/cm. 19, 20 As reported previously, HRG appeared as a closely migrating doublet on SDS-PAGE under nonreducing and reducing conditions (not shown).
12
The identity of HRG was confirmed by NH 2 Biophen CS11-22, absorbance was measured at 405 nm in a plate reader (Molecular Devices, Sunnyvale CA). Rates of cleavage of the chromogenic substrate were normalized relative to that obtained in the absence of HRG, and plotted against HRG concentration. Data were analyzed with TableCurve 2D (Jandel Scientific Software, SPSS Inc., Chicago, IL) using a rectangular hyperbola equation to determine the concentration of HRG required to produce 50% inhibition of activation (IC 50 ). In similar experiments, 1% APTT-SP, 2 μg/ml dextran sulfate, or 10 μg/ml silica was used in place of polyphosphate. Experiments with silica were performed in the absence or presence of 3 µM fibrinogen.
Influence of HRG on f.XI activation by f.XIIa. The effect of HRG on f.XI activation by f.XIIa was examined in the presence of APTT-SP and HK. Samples containing 10 nM f.XIIa, 100 nM HK, 120 nM f.XI, 10% APTT-SP, and 0-2 μΜ HRG in HBS containing 2 mM CaCl 2 and 12.5 μΜ ZnCl 2 were incubated at 37ºC. After 60 min, aliquots were removed and the extent of f.XI activation was determined by monitoring f.XIa-mediated hydrolysis of 600 μM S-2366. Values were normalized relative to that obtained in the absence of HRG and the IC 50 was determined as described above.
Influence of HRG on f.XII activation by kallikrein. SDS-PAGE was used to monitor the activation of 2.5 µM f.XII by 100 nM kallikrein in a mixture of 2 μg/ml dextran sulfate, 12.5 μM CTI, 2 mM CaCl 2 and 12.5 μM ZnCl 2 in the absence or presence of HRG. At time points ranging from 0-2 h, 10 μl aliquots of containing 2 μg f.XII were removed and subjected to SDS-PAGE under reducing conditions. In the reciprocal experiment, the influence of HRG on prekallikrein activation by f.XIIa was monitored in the absence or presence of 600 nM HK.
After incubation of 120 nM prekallikrein with 2 nM f.XIIa in TBS containing 2mM CaCl 2 , 12.5 µM ZnCl 2 and 0.5 µg/ml dextran sulfate for 2 min, kallikrein generation was monitored using S-
2302.
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To stop the reaction, 16 μM glycine, pH 8.0, was added and free biotin was removed by passage over a PD-10 column (GE Healthcare) equilibrated with HBS. Biotin-hydrazide was reacted with deaminated heparin at a 10:1 molar ratio. The sample was dialyzed against water and the biotin-labelled heparin was lyophilized and its concentration determined by mass. f.XIIa was biotin-labeled at its active site by reaction with biotin-Phe-Pro-Arg chloromethyl ketone (b-FPR;
Haematological Technologies Inc., Essex Junction, VT).
Surface plasmon resonance. Biomolecular interaction analysis was performed on the Biacore T100 biosensor system (Biacore AB, Uppsala, Sweden). Biotinylated-HRG was adsorbed to 800
Response Units (RU) onto a Series S sensor chip SA in HBS-Tw at a flow rate of 5 µl/min. An Clotting assays. In a multiwell plate, 90 µl aliquots of citrated, normal pooled human plasma were incubated with 0-5 µM HRG for 10 min at 37ºC prior to addition of 10 µl of 260 mM CaCl 2 and 10 µl of APTT-SP. The plate was then read at 405 nm for 30 min at 37ºC and the time to reach half maximal absorbance was determined by the instrument software (clot time). To examine tissue factor-mediated clotting, Recombiplastin, at 1/10 dilution, was substituted for APTT-SP. Additional assays were performed in HRG-deficient plasma that was first dialyzed against TBS to remove citrate. In these assays, clotting was initiated with 8 nM f.XIIa, 1.5 nM f.IXa, or 2 nM f.XIa, which was added to 100 µl plasma together with 2 mM CaCl 2 , 15 µM ZnCl 2, and 0-5 µM HRG in a total volume of 160 µl. f.XIIa-mediated clotting of normal plasma was also assessed in the absence or presence of 3.5 mg/ml sheep anti-HRG antibody or control sheep IgG (Sigma).
Determination of plasma HRG concentration.
The concentration of HRG in normal plasma was determined to be 1.6 µM by SPR (see Supplementary Information).
Influence of HRG on inhibition of f.XIIa by C1 inhibitor or CTI. See Supplementary Information.
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Detection of HRG-f.XIIa complexes in plasma. See Supplementary Information.
Results
Effect of HRG on plasma clotting times. HRG was added to normal citrated plasma and clotting was initiated with tissue factor or APTT-SP to examine the effect of HRG on the extrinsic and intrinsic pathways, respectively. HRG had little effect on tissue factor-induced clotting, where the clotting times in the absence and presence of 3.2 µM HRG were 79.7 ± 2.1 and 83.8 ± 4.9 s, respectively (p=0.47). In contrast, the activated partial thromboplastin time of control plasma (248 ± 4 s) was 4-fold longer in the presence of 2 µM HRG (1057 ± 127 s; p=0.008). These data suggest that HRG affects clotting through the intrinsic pathway and does not influence the extrinsic pathway.
To examine this more closely, the effect of added HRG on clotting of HRG-deficient plasma was examined. To minimize the impact of plasma processing, control plasma was subjected to chromatography on unmodified Sepharose. In the APTT assay, HRG-deficient plasma clotted two-fold more rapidly than control plasma (216 ± 24.1 and 426 ±10.1 s, respectively; p<0.001). These data confirm that HRG attenuates the contact pathway of clotting.
When HRG was added back to the deficient plasma, a dose dependent and saturable increase in clotting time was observed (Fig. 1) .
To identify where HRG was affecting the contact system, we next examined its effect on clotting of HRG-deficient plasma initiated by f.XIIa, f.XIa or f.IXa. HRG prolonged the f.XIIamediated clotting time by 81% and 102% at 2.5 and 5 µM, respectively (Fig. 2) . In contrast, HRG had little effect on f.XIa-or f.IXa-mediated clotting times. These results suggest that HRG prolongation of the APTT reflects an effect on f.XIIa. To confirm this, we measured the APTT in the absence or presence of the HRG-directed antibody. Antibody addition shortened the clotting time from 358 ± 55 s to 140 ± 19 s ( Fig. 3 ; p=0.02), whereas a nonspecific antibody had no effect. (Fig. 5A) . HRG inhibited f.XII autoactivation by over 95% and inhibition was concentration-dependent with an IC 50 of 115 nM.
HRG also inhibited autoactivation mediated by APTT-SP, silica, or dextran sulfate in a similar fashion (not shown). Although this activity could reflect the capacity of HRG to bind and neutralize the activator, further investigation revealed that HRG binds dextran sulfate but not silica, the active agent in APTT-SP (not shown). These data suggest that HRG does not attenuate coagulation simply by compromising the contact activator.
To begin to investigate the mechanism by which HRG inhibits f.XII activation, control experiments were first performed to determine whether HRG binds to the active site of f.XIIa in the presence of Zn 2+ . HRG had variable effects on f.XIIa chromogenic activity, depending on the substrate (not shown). With S-2222, no effect of HRG was observed. In contrast, with Pefachrome XIIa, 2 µM HRG promoted f.XIIa activity by 35%, raising the possibility that HRG Effect of HRG on the kallikrein system. Because prekallikrein and f.XIIa comprise an autolytic feedback loop, reactions involving these factors in their zymogen or active forms were examined. The effect of HRG on the activation of f.XII by kallikrein in the presence of Zn 2+ was examined first. To avoid autoactivation of f.XII by f.XIIa, CTI was added to inhibit any f.XIIa that was formed and SDS-PAGE analysis was used to monitor f.XII activation. In the presence of 2 µM HRG, activation of f.XII by kallikrein was reduced by 50% (not shown). These results demonstrate that HRG has only a modest inhibitory effect on kallikrein activity. In the reciprocal experiment, the effect of HRG on the activation of PK by f.XIIa in the presence of To ensure that modification or adsorption of either protein to the SA chip did not lead to spurious results, an additional control was performed in which both proteins were unmodified.
SPR experiments revealed that HRG binds heparin with a Kd value of 2 nM in the presence of Zn 2+ , whereas f.XII and f.XIIa do not bind heparin (not shown). Therefore, biotin-heparin was adsorbed to a SA chip and binding of HRG was examined in the absence or presence of f.XIIa.
Injection of HRG in the presence of Zn 2+ revealed high affinity binding to immobilized heparin (Fig. 7) . In the presence of increasing concentrations of f.XIIa, binding of HRG to heparin was reduced in a dose-dependent fashion. At 100 nM f.XIIa, binding of HRG to heparin was completely inhibited. This result confirms the interaction of HRG with f.XIIa and suggests that heparin and f.XIIa share the same binding site on HRG. In contrast, zymogen f.XII had no effect on the binding of HRG to heparin (not shown). In additional SPR experiments, it was observed that neither f.XIa nor f.XI binds to immobilized HRG, whereas kallikrein binds HRG with a Kd value of 340 nM (not shown).
Modulation of HRG activity by fibrinogen. It is apparent that the concentration of HRG required
to modulate plasma clotting assays is higher than expected, given that the Kd for f.XIIa is 21 nM in buffer systems without Zn 2+ . One potential explanation is that the interaction of HRG with other plasma proteins attenuates its effect on f.XIIa. To explore this, the effect of fibrinogen on HRG modulation of f.XII autoactivation was examined. Although polyphosphate-mediated autoactivation of f.XII was inhibited by 50% at 350 nM HRG, the IC 50 increased 5-fold to 2000 nM in the presence of 3 µM fibrinogen (not shown). Thus, considering the number of plasma proteins that bind HRG, 22 it is likely that higher concentrations of HRG are required to attenuate
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HRG-f.XIIa complexes in plasma.
An enzyme immunoassay was used to assess the formation of HRG-f.XIIa complexes in plasma activated with APTT-SP. Activated plasma yielded an f.XIIa-HRG complex concentration of 5 µg/ml, whereas no complexes were detected in unactivated normal plasma or f.XII deficient plasma. The concentration of f.XIIa-HRG complexes detected in plasma after APTT-SP addition represents 10-20% of the normal plasma concentration of f.XII.
Discussion
Emerging evidence suggests that the intrinsic pathway of coagulation contributes to thrombosis at sites of vascular injury. 23, 24 This has prompted the development of novel anticoagulants that target this pathway. 4, 25 The success of such an approach depends on an understanding of how the intrinsic pathway is regulated. Because the intrinsic pathway is initiated by the activation of f.XII, an understanding of f.XIIa regulation is particularly important. The current study was prompted by our initial observation that HRG addition to plasma prolongs the activated partial thromboplastin time, but has no effect on the prothrombin time. In accordance with this observation, HRG attenuated clotting initiated by f.XIIa, but not by f.XIa or f.IXa. We showed that HRG binds f.XIIa with high affinity and inhibits its capacity to autoactivate f.XII or to activate f.XI. We also detected HRG-f.XIIa complexes in contactactivated plasma. These findings raise the possibility that HRG modulates the intrinsic pathway of coagulation. In support of this concept, immunodepletion of HRG from plasma or addition of an HRG-directed antibody resulted in a shorter activated partial thromboplastin time, whereas HRG supplementation of HRG-deficient plasma prolonged this clotting time.
The available data suggest a mechanism by which HRG and f.XIIa interact. Because Zn 2+ heightens the affinity of f.XIIa for HRG by over 3 orders of magnitude, the histidine-rich region
HRG is mediated by its NH 2 -terminal cystatin domains and not its histidine-rich domain, suggesting that Zn 2+ binding to the histidine-rich domain modulates other domains in HRG. [26] [27] [28] [29] Because heparin disrupts the interaction of HRG with f.XIIa, it is possible that f.XIIa also binds to the cystatin domains and that the affinity of this interaction is heightened by Zn 2+ binding to the histidine-rich domain. With respect to f.XIIa, the catalytic domain f.XIIa can be excluded because β -f.XIIa does not bind HRG. This leaves the heavy chain of f.XII as the binding site for HRG. The conformational change 30 in f.XII zymogen evoked by Zn 2+ is insufficient to promote HRG binding. Therefore, the HRG binding site must be cryptic on f.XII and only exposed when it is converted to f.XIIa. This is analogous to the interaction with fibronectin and a monoclonal antibody against the kringle domain of f.XII; these proteins bind f.XIIa, but not zymogen f.XII. 31, 32 Chromogenic assays reveal that HRG binds to a site distinct from the active site of f.XIIa. Furthermore, HRG does not impair the capacity of either CTI or C1 inhibitor to inhibit f.XIIa. Therefore, it is likely that HRG binds to an exosite on f.XIIa that mediates f.XIIa binding to macromolecular substrates.
The specificity and avidity of HRG binding to f.XIIa and the inhibitory effects of HRG on f.XIIa activity imply a physiological role for the interaction. Current thinking is that C1
inhibitor is the physiological inhibitor of f.XIIa, although the second order rate constant suggests that inhibition is slow. 33, 34 Given the high affinity of HRG for f.XIIa and the abundance of HRG in plasma, HRG is more likely to bind f.XIIa than is C1 inhibitor. The affinity of f.XIIa for HRG is increased in the presence of Zn 2+ . Although Zn 2+ also binds and modulates f.XIIa activity, 30, 35 the effect of HRG is not Zn 2+ -dependent because HRG binds f.XIIa and modulates clotting even in the absence of Zn 2+ . However, f.XIIa will bind HRG even more avidly at sites of vascular injury where platelet activation leads to release of Zn 2+ from α -granules. 36 The HRG-f.XIIa interaction would serve to attenuate f.XIIa-mediated activation of the contact pathway, thereby
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Despite the potential for further complexity, our data suggest that HRG modulates f.XIIamediated initiation of the contact pathway, thereby limiting systemic f.XIIa activation and localizing the procoagulant response.
HRG is proposed to play a role in numerous processes, including angiogenesis, apoptosis, and immune regulation (reviewed in 11, 22 ) . In a knockout model, mice lacking HRG exhibited a procoagulant phenotype, although involvement of the contact pathway was not examined.
14 Furthermore, HRG deficiency in humans has been associated with a thrombotic phenotype, at least in some individuals. 38 The current description of modulation of the contact system reveals a potential new function for HRG. In support of this concept, a genome wide association study aimed at investigating factors that influence the activated partial thromboplastin time identified highly associated polymorphisms in the genes for f.XII, HK, and HRG. 39 The means by which HRG modulates the activated partial thromboplastin time may depend on local conditions. In the absence of vascular injury, HRG is unlikely to affect hemostasis because it does not bind f.XII zymogen and because free Zn 2+ levels in plasma are below 1 µM. 21 When f.XII is activated at sites of injury and local Zn 2+ levels increase in response to platelet activation, HRG can bind f.XIIa with high affinity. HRG is a potent inhibitor of f.XIIa procoagulant activity and its plasma levels are relatively high and do not fluctuate widely, except in pathological states because HRG is a negative acute phase protein. 40 Therefore, rather than acting as a dynamic inhibitor of f.XIIa, HRG is more likely to serve as a reservoir for f.XIIa formed in situ or for f.XIIa that has escaped from the site of injury. In this way, HRG may compensate for the low rate of f.XIIa inhibition by C1 inhibitor. Because HRG binds fibrin 41 , it is conceivable that HRG is retained within the fibrin clot where it is poised to modulate f.XIIa-mediated activation of coagulation. Thus, in addition to its proposed role in fibrinolysis 11, 22 , HRG may also serve as an effector of coagulation. The homology of HRG with HK, a key modulator of the contact system, provides further support for this proposal. 42 Both proteins have cystatin-like and histidine-rich domains and bind glycosaminoglycans, Zn 2+ and various enzymatic forms of the contact factors. 43 However, HK promotes activation of contact factors and protects f.XIa and kallikrein from inhibition by antithrombin, whereas HRG inhibits activation of f.XII and has no effect on f.XIIa inhibition. Thus, HRG may serve to offset the action of HK and limit propagation of the contact system. In conclusion, with emerging evidence for the role of the contact system in the pathogenesis of thrombosis at sites of vascular injury, our data suggest that HRG may be an important regulator of thrombogenesis. 
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